Adoptive T cell therapy for cancer in the clinic

J Clin Invest. 2007 Jun;117(6):1466-76. doi: 10.1172/JCI32446.


The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Genetic Engineering
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes, Cytotoxic / immunology


  • Cancer Vaccines